149 related articles for article (PubMed ID: 31394044)
1. Safety of bazedoxifene in Korean women with post-menopausal osteoporosis: a post-marketing surveillance study (PMSS).
Kim JW; Lee JY; Park HE; Kim SH; Chung YS
Expert Opin Drug Saf; 2019 Oct; 18(10):1001-1008. PubMed ID: 31394044
[No Abstract] [Full Text] [Related]
2. Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled Phase 3 study of postmenopausal women with osteoporosis.
Christiansen C; Chesnut CH; Adachi JD; Brown JP; Fernandes CE; Kung AW; Palacios S; Levine AB; Chines AA; Constantine GD
BMC Musculoskelet Disord; 2010 Jun; 11():130. PubMed ID: 20569451
[TBL] [Abstract][Full Text] [Related]
3. Assessment of the safety of long-term bazedoxifene treatment on the reproductive tract in postmenopausal women with osteoporosis: results of a 7-year, randomized, placebo-controlled, phase 3 study.
Palacios S; de Villiers TJ; Nardone Fde C; Levine AB; Williams R; Hines T; Mirkin S; Chines AA;
Maturitas; 2013 Sep; 76(1):81-7. PubMed ID: 23871271
[TBL] [Abstract][Full Text] [Related]
4. Bazedoxifene: a selective estrogen-receptor modulator.
Mitwally MF
Womens Health (Lond); 2008 Jul; 4(4):319-26. PubMed ID: 19072496
[TBL] [Abstract][Full Text] [Related]
5. A 7-year randomized, placebo-controlled trial assessing the long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: effects on bone density and fracture.
Palacios S; Silverman SL; de Villiers TJ; Levine AB; Goemaere S; Brown JP; De Cicco Nardone F; Williams R; Hines TL; Mirkin S; Chines AA;
Menopause; 2015 Aug; 22(8):806-13. PubMed ID: 25668306
[TBL] [Abstract][Full Text] [Related]
6. Bazedoxifene: bazedoxifene acetate, TSE 424, TSE-424, WAY 140424.
Drugs R D; 2008; 9(3):191-6. PubMed ID: 18457472
[TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial.
de Villiers TJ; Chines AA; Palacios S; Lips P; Sawicki AZ; Levine AB; Codreanu C; Kelepouris N; Brown JP
Osteoporos Int; 2011 Feb; 22(2):567-76. PubMed ID: 20535606
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of bazedoxifene, a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis.
Palacios S
Curr Med Res Opin; 2010 Jul; 26(7):1553-63. PubMed ID: 20429824
[TBL] [Abstract][Full Text] [Related]
9. Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women.
Archer DF; Pinkerton JV; Utian WH; Menegoci JC; de Villiers TJ; Yuen CK; Levine AB; Chines AA; Constantine GD
Menopause; 2009; 16(6):1109-15. PubMed ID: 19543129
[TBL] [Abstract][Full Text] [Related]
10. A double-blind, randomized, ascending, multiple-dose study of bazedoxifene in healthy postmenopausal women.
McKeand WE; Orczyk GP; Ermer JC; Chines AA
Clin Pharmacol Drug Dev; 2014 Jul; 3(4):262-9. PubMed ID: 27128831
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic evaluation of bazedoxifene for the treatment of osteoporosis.
Gatti D; Rossini M; Sblendorio I; Lello S
Expert Opin Drug Metab Toxicol; 2013 Jul; 9(7):883-92. PubMed ID: 23621618
[TBL] [Abstract][Full Text] [Related]
12. Gynecologic Safety of Conjugated Estrogens Plus Bazedoxifene: Pooled Analysis of Five Phase 3 Trials.
Mirkin S; Pinkerton JV; Kagan R; Thompson JR; Pan K; Pickar JH; Komm BS; Archer DF
J Womens Health (Larchmt); 2016 May; 25(5):431-42. PubMed ID: 27058301
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of bazedoxifene for postmenopausal osteoporosis.
Kawate H; Takayanagi R
Clin Interv Aging; 2011; 6():151-60. PubMed ID: 21753870
[TBL] [Abstract][Full Text] [Related]
14. Effects of bazedoxifene in nonflushing postmenopausal women: a randomized phase 2 trial.
Bachmann G; Crosby U; Feldman RA; Ronkin S; Constantine GD
Menopause; 2011 May; 18(5):508-14. PubMed ID: 21289525
[TBL] [Abstract][Full Text] [Related]
15. Bazedoxifene: a third-generation selective estrogen receptor modulator for treatment of postmenopausal osteoporosis.
Stump AL; Kelley KW; Wensel TM
Ann Pharmacother; 2007 May; 41(5):833-9. PubMed ID: 17426077
[TBL] [Abstract][Full Text] [Related]
16. Bazedoxifene and bazedoxifene combined with conjugated estrogens for the management of postmenopausal osteoporosis.
Lewiecki EM
Expert Opin Investig Drugs; 2007 Oct; 16(10):1663-72. PubMed ID: 17922629
[TBL] [Abstract][Full Text] [Related]
17. Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis.
Pinkerton JV; Archer DF; Utian WH; Menegoci JC; Levine AB; Chines AA; Constantine GD
Menopause; 2009; 16(6):1102-8. PubMed ID: 19546825
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of bazedoxifene in postmenopausal Asian women.
Xu L; Tsai KS; Kim GS; Wu Y; Vincendon P; Chines AA; Constantine GD
Osteoporos Int; 2011 Feb; 22(2):559-65. PubMed ID: 20535607
[TBL] [Abstract][Full Text] [Related]
19. Bazedoxifene: a new selective estrogen receptor modulator for postmenopausal osteoporosis.
Genant HK
Menopause Int; 2011 Jun; 17(2):44-9. PubMed ID: 21693498
[TBL] [Abstract][Full Text] [Related]
20. Bazedoxifene acetate for the management of postmenopausal osteoporosis.
Palacios S
Drugs Today (Barc); 2011 Mar; 47(3):187-95. PubMed ID: 21494696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
